Biomarkers are however lacking for the other etiologies and analysis of AD biomarkers in CSF (t-tau, p-tau, amyloid peptides) remains recommended to exclude this pathology as it is the main differential diagnosis for degenerative dementia (Ducharme et al., 2020). This evidence concerns the gene MAPT and Alzheimer disease.